This site is intended for healthcare professionals
Drug news

FDA gives tentative approval for dolutegravir + emtricitabine + tenofovir alafenamide in HIV/AIDS.- Mylan.

Read time: 1 mins
Last updated:21st Feb 2018
Published:21st Feb 2018
Source: Pharmawand

Mylan N.V. announced receipt of tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for dolutegravir, emtricitabine, and tenofovir alafenamide Tablets, 50 mg/200 mg/25 mg. The antiretroviral (ARV) will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS.

The tablet will be the smallest sized single-tablet regimen available for patients in the developing world. It will be offered in a 90-day package as well as a 30-day one, potentially allowing patients fewer trips to the clinics for a refill.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.